Enoxiprne full detail

Reading File

Finding Sources

Searching the Web

enoxaparin pharmacology mechanism dose indications 2025

Searching PubMed

enoxaparin anticoagulation clinical use

Reading File

Finding Sources

Reading Web Page

enoxaparin mechanism dose indications adverse effects monitoring reversal

Reading File

I now have comprehensive information from multiple textbooks and sources. Let me compile the full detailed response.

Enoxaparin - Full Pharmacological Profile

Note: You wrote "Enoxiprne" - this appears to be a spelling variant of Enoxaparin (brand name: Lovenox). The full details below are for enoxaparin.

1. Classification & Overview

Enoxaparin is a low molecular weight heparin (LMWH) with antithrombotic properties. It is derived from unfractionated heparin (UFH) through controlled depolymerization of porcine intestinal mucosa heparin. The mean molecular weight is approximately 4,000 Da (~15 saccharide units), compared to UFH's mean of ~15,000 Da.

First approved for medical use: 1993
Brand name: Lovenox (and generics)
Doses specified in milligrams (not anti-Xa units like dalteparin)
1 mg enoxaparin = 100 anti-Xa IU

2. Mechanism of Action

Enoxaparin works indirectly through antithrombin (AT):

Enoxaparin binds to AT via a unique pentasaccharide sequence, causing a conformational change that exposes AT's active site.
This accelerates AT's inhibition of clotting factor proteases by approximately 1,000-fold.
Because of its shorter chain length, enoxaparin preferentially inhibits Factor Xa over Factor IIa (thrombin):
- ~25-50% of enoxaparin molecules contain ≥18 saccharide units and can inhibit both Factor Xa and Factor IIa
- ~50-75% contain <18 saccharide units and only inhibit Factor Xa
The anti-Factor Xa to anti-Factor IIa ratio is approximately 14:1 (vs. UFH's ratio of ~1.2:1)

Key difference from UFH: Enoxaparin is less effective against clot-bound thrombin. UFH, with its longer chains, bridges AT to thrombin and inhibits both free and clot-bound thrombin more broadly.

Miller's Anesthesia, 10e, p. 6760
Katzung's Basic and Clinical Pharmacology, 16e, p. 959

3. Pharmacokinetics

Parameter	Details
Route	Subcutaneous (SC) injection; IV bolus in specific scenarios (e.g., PCI)
Bioavailability (SC)	~92% (much higher than UFH's variable 30%)
Peak anti-Xa activity	~4 hours after SC dose
Half-life	~4.5 hours (longer than UFH's 30 min - 2 hrs)
Elimination	Primarily renal; reduced clearance with CrCl <30 mL/min
Monitoring	Not usually required; predictable pharmacokinetics at normal renal function
Effect on aPTT/PT	Minimal effect at therapeutic doses - does NOT prolong aPTT reliably

4. FDA-Approved Indications & Dosing

4a. DVT Treatment

Patient	Dose
Adult (inpatient DVT ± PE)	1 mg/kg SC Q12h OR 1.5 mg/kg SC Q24h
Adult (outpatient DVT without PE)	1 mg/kg SC Q12h
Premature neonate	2 mg/kg/dose Q12h SC
Full-term neonate	1.7 mg/kg/dose Q12h SC
Infant 1-<2 months	1.5 mg/kg/dose Q12h SC
Child ≥2 months - adult	1 mg/kg/dose Q12h SC

4b. DVT Prophylaxis

Setting	Dose
Abdominal surgery	40 mg SC Q24h (start 2h pre-op, continue 7-10 days)
Hip replacement surgery	30 mg SC Q12h OR 40 mg SC Q24h
Knee replacement surgery	30 mg SC Q12h for 7-10 days
Medical patients (acutely ill)	40 mg SC Q24h for 6-11 days
Extended prophylaxis post-discharge	40 mg SC Q24h for 28±4 days (EXCLAIM trial)
Pediatric (≥2 mo - 18 yr)	0.5 mg/kg/dose Q12h SC; max 30 mg/dose

4c. Acute Coronary Syndromes (ACS)

Indication	Dose
NSTEMI / Unstable Angina	1 mg/kg SC Q12h + aspirin 100-325 mg/day
STEMI (with thrombolysis)	30 mg IV bolus, then 1 mg/kg SC Q12h (max 100 mg for first 2 doses); given 15 min before to 30 min after fibrinolytic
STEMI (age >75 years)	No IV bolus; 0.75 mg/kg SC Q12h (max 75 mg first 2 doses)
PCI (last SC dose >8h before balloon)	0.3 mg/kg IV bolus

4d. Pulmonary Embolism

Same as DVT treatment doses above; bridge to oral anticoagulation

4e. Off-Label Uses

VTE prevention in cancer patients
Periprocedural anticoagulation (bridging therapy)
Antiphospholipid syndrome in pregnancy
Lateral sinus thrombosis
Acute ischemic stroke with cardioembolic source
Harriet Lane Handbook, 23e | Tintinalli's Emergency Medicine | NIH/StatPearls

5. Dosage Adjustments

Renal Impairment (CrCl <30 mL/min - severe)

Indication	Adjusted Dose
Prophylaxis (any surgical/medical)	30 mg SC once daily
DVT treatment (inpatient)	1 mg/kg SC once daily
DVT treatment (outpatient)	1 mg/kg SC once daily
STEMI treatment	1 mg/kg SC once daily

Dosages of enoxaparin cannot be substituted mg-for-mg with other LMWHs due to pharmacokinetic differences.

Obesity

Weight-based dosing continues for therapeutic use (1 mg/kg); however, anti-Xa monitoring is recommended in severely obese patients (BMI >40) - dosing strategies vary
A recent systematic review (PMID: 39109860) examined therapeutic enoxaparin dosing specifically in obesity

Hepatic Impairment

No formal dose reduction required; use caution due to bleeding risk

6. Monitoring

Anti-Xa monitoring is not routinely required but is indicated in:

Renal failure (CrCl <30 mL/min)
Morbid obesity
Pregnancy
Extremes of body weight (<50 kg or >80 kg)
Pediatric patients

Anti-Xa target levels (measured 4 hours post-dose):

Purpose	Target Anti-Xa Level
DVT treatment (Q12h dosing)	0.5 - 1.0 units/mL
DVT prophylaxis	0.1 - 0.4 units/mL

Important: Anti-Xa LMWH level is NOT the same as the anti-Xa used for UFH monitoring.

Harriet Lane Handbook, 23e | Katzung, 16e

7. Adverse Effects

Major

Hemorrhage - most common serious adverse effect; risk increased by advanced age (>75), female sex, renal failure, concurrent antiplatelet agents, low body weight
Heparin-Induced Thrombocytopenia (HIT) - immune-mediated thrombocytopenia (platelet factor 4-antibody complex). Risk is lower with LMWH than UFH, but still possible. Manifests as paradoxical thrombosis
Spinal/epidural hematoma - rare but life-threatening; risk increased with neuraxial anesthesia, spinal puncture, or indwelling epidural catheters

Moderate / Other

Injection site pain, erythema, bruising, hematoma
Thrombocytopenia (non-immune, mild)
Hypochromic anemia
Elevated liver transaminases (transient)
Osteoporosis with prolonged use (less than UFH)
Alopecia (rare)
Eosinophilia
Allergic reactions (contains pork proteins)
Hypersensitivity / anaphylaxis
Harriet Lane Handbook, 23e, p. 1124

8. Contraindications

Absolute

Active major bleeding
Drug-induced thrombocytopenia (heparin-induced)
Hypersensitivity to enoxaparin or pork products

Relative

Platelets ≤50,000/mm³
Uncontrolled arterial hypertension
Bleeding diathesis
Recurrent GI ulcers
Diabetic retinopathy
Severe renal dysfunction (GFR <30 mL/min) - dose adjust rather than avoid
Recent brain, spinal cord, or eye surgery
Neuraxial anesthesia (timing precautions required)
Intramuscular injection
Harriet Lane Handbook, 23e | Katzung's Basic and Clinical Pharmacology, 16e

9. Drug Interactions

Drug/Class	Interaction
Antiplatelet agents (aspirin, clopidogrel, GP IIb/IIIa inhibitors)	Additive bleeding risk
NSAIDs	Increased hemorrhagic risk
Warfarin / other anticoagulants	Additive anticoagulation
Thrombolytics	Increased bleeding risk
Systemic corticosteroids	Increased bleeding risk
Dextran	Additive antiplatelet/anticoagulant effect

10. Reversal

Protamine sulfate is the reversal agent:

1 mg protamine neutralizes approximately 1 mg enoxaparin
Protamine only partially reverses LMWH because it requires >14 saccharide units for interaction with heparin; the shorter LMWH chains are incompletely neutralized
Protamine does not completely abolish anti-Xa activity, but neutralizes the higher molecular weight fractions
Risk of anaphylaxis with protamine (especially in patients with fish allergy or prior protamine exposure)

Dosing for reversal:

If enoxaparin given in past ≤8 hours: 1 mg protamine per 1 mg enoxaparin (max 50 mg)
If 8-12 hours since last dose: 0.5 mg protamine per 1 mg enoxaparin
If >12 hours since last dose: protamine generally not required
Tintinalli's Emergency Medicine | Miller's Anesthesia, 10e

11. Use in Special Populations

Pregnancy

Enoxaparin does not cross the placenta - considered safer than warfarin in pregnancy
Preferred anticoagulant for VTE treatment/prophylaxis in pregnancy
Monitor with anti-Xa levels due to changing pharmacokinetics
Discontinue 24 hours before planned delivery or neuraxial anesthesia

Elderly (>75 years)

Increased bleeding risk - reduce STEMI dosing (0.75 mg/kg Q12h, no initial bolus)
Renal function must be assessed carefully

Pediatric Patients

Higher weight-based doses required due to larger volume of distribution
Anti-Xa monitoring mandatory in all pediatric patients
See dosing table in Section 4 above

Renal Impairment

Enoxaparin is renally cleared - accumulation occurs with CrCl <30 mL/min
Dose reduce to once-daily dosing; see tables in Section 5

12. Perioperative Use

Per American College of Chest Physicians (ACCP) guidelines:

Last pre-surgical dose at least 24 hours before surgery
Can restart 12 hours after surgery if hemostasis is adequate
For neuraxial anesthesia: last dose ≥12h before catheter placement for prophylactic doses; ≥24h for therapeutic doses; do not remove catheter until ≥12h after last dose; next dose ≥4h after catheter removal

13. Comparison: Enoxaparin vs UFH

Feature	Enoxaparin (LMWH)	Unfractionated Heparin (UFH)
Molecular weight	~4,000 Da	~15,000 Da
Anti-Xa:IIa ratio	~14:1	~1.2:1
Bioavailability (SC)	~92%	~30% (variable)
Dosing	Once or twice daily SC	Continuous IV infusion
Monitoring	Usually not needed	aPTT mandatory
HIT risk	Lower (~0.1%)	Higher (1-4%)
Reversal	Partial with protamine	Full reversal with protamine
Renal clearance	Yes (dose adjust)	Minimal (safer in renal failure)
Active vs clot-bound thrombin	Partial	More effective
Clinical outcomes (ACS)	15-20% reduction in death/MI vs UFH	Reference standard

14. Key Clinical Trial Evidence

ESSENCE trial (1997): Enoxaparin + aspirin more effective than UFH + aspirin in NSTEMI - reduced composite of death, AMI, and recurrent ischemia
ExTRACT-TIMI 25: Enoxaparin superior to UFH in STEMI patients receiving fibrinolysis
EXCLAIM trial: Extended-duration prophylaxis (28 days) post-discharge reduced VTE vs standard 10-day course in acutely ill medical patients
Recent meta-analysis (PMID: 41058290) found rivaroxaban non-inferior to enoxaparin for VTE prevention after knee surgery with comparable wound complications

15. Available Formulations

100 mg/mL concentration - single-dose prefilled syringes: 30 mg/0.3 mL, 40 mg/0.4 mL; graduated prefilled syringes: 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL; multiple-dose vial: 300 mg/3 mL
150 mg/mL concentration - graduated prefilled syringes: 120 mg/0.8 mL, 150 mg/mL
Multidose vial contains benzyl alcohol 15 mg/mL as preservative (avoid in neonates)
Single-dose syringes are preservative-free

Enoxiprne dose for MI

Finding Sources

Searching the Web

enoxaparin dose STEMI NSTEMI myocardial infarction 2024 guidelines

Reading File

Here is a focused, complete reference for enoxaparin dosing in myocardial infarction:

Enoxaparin Dosing in Myocardial Infarction

NSTEMI / Unstable Angina

Scenario	Dose
Standard	1 mg/kg SC every 12 hours + aspirin 75-325 mg/day
Initial IV loading dose (optional per AHA/ACC)	30 mg IV bolus, then 1 mg/kg SC Q12h
Duration	Minimum 2 days; continue for hospitalization duration or until PCI is performed (usually 2-8 days)
Renal impairment (CrCl <30 mL/min)	1 mg/kg SC once daily

Level of Evidence A (AHA/ACC NSTE-ACS guidelines). Anticoagulation is recommended for ALL patients with NSTEMI regardless of management strategy (conservative or invasive).

STEMI - With Fibrinolytic Therapy

This is the primary setting where enoxaparin is preferred over UFH.

Patient Group	Dose
Age <75 years	30 mg IV bolus, then 15 min later 1 mg/kg SC Q12h (max 100 mg for first 2 doses)
Age ≥75 years	No IV bolus - give 0.75 mg/kg SC Q12h (max 75 mg for first 2 doses)
Any age + CrCl <30 mL/min	No IV bolus - give 1 mg/kg SC once daily

Timing relative to fibrinolytic:

Give enoxaparin between 15 minutes before and 30 minutes after the start of fibrinolytic therapy
All patients should receive aspirin 75-325 mg/day concurrently
Duration: up to 8 days or until hospital discharge (whichever comes first)

STEMI - With Primary PCI (pPCI)

Scenario	Dose
Patient already on enoxaparin at time of PCI, last SC dose <8 hours before balloon inflation	No additional dose required
Last SC dose >8 hours before balloon inflation	Give 0.3 mg/kg IV bolus at time of PCI
Starting enoxaparin de novo for PCI	0.5-0.75 mg/kg IV bolus (some protocols)

Note: UFH or bivalirudin remain more commonly used for primary PCI in most centres. AHA/ACC guidelines do not list LMWH as preferred for primary PCI, but ESC STEMI and revascularization guidelines do recommend enoxaparin as an alternative. If a patient was started on enoxaparin before PCI, do not switch to UFH (switching agents increases bleeding risk - SYNERGY trial).

Quick Summary Table

Indication	Standard Dose	Age/Renal Adjustment
NSTEMI/UA	1 mg/kg SC Q12h	CrCl <30: 1 mg/kg SC Q24h
STEMI + fibrinolysis, age <75	30 mg IV bolus → 1 mg/kg SC Q12h (max 100 mg ×2)	-
STEMI + fibrinolysis, age ≥75	0.75 mg/kg SC Q12h (max 75 mg ×2); no bolus	-
STEMI + fibrinolysis, any age, CrCl <30	1 mg/kg SC Q24h; no bolus	Regardless of age
STEMI → PCI (last dose <8h)	No additional dose	-
STEMI → PCI (last dose >8h)	0.3 mg/kg IV bolus	-

Key Clinical Points

Do not switch between enoxaparin and UFH once therapy is started - this increases bleeding without improving outcomes (SYNERGY trial)
Enoxaparin outperformed UFH in STEMI patients receiving fibrinolysis in large trials (ExTRACT-TIMI 25); 15-20% reduction in death/MI vs UFH in NSTEMI (ESSENCE trial)
Enoxaparin is not first-line for patients going directly to primary PCI; however it is safe to continue if already started
In patients >75 years or with renal impairment, the risk of intracranial bleeding is higher - omit the IV bolus and reduce dose
Monitor with anti-Xa levels (target 0.5-1.0 units/mL for therapeutic dosing) only in renally impaired, obese, or pregnant patients

Nstemi management or injection dose

Finding Sources

Searching the Web

NSTEMI management guidelines 2024 ACC AHA drugs doses

Finding Sources

Reading File

Excellent - I now have comprehensive data. Here is the full NSTEMI management guide with all injection doses:

NSTEMI - Complete Management & Injection Doses

Step 1 - Immediate Assessment & Monitoring

Admit to hospital, continuous ECG monitoring for ST deviation and arrhythmias
Bed rest initially; ambulation permitted after 24h if no recurrent ischemia or troponin rise
IV access, pulse oximetry, serial vital signs
Serial high-sensitivity troponin (hsTn): at presentation, 1h, and 3h if needed
Oxygen: only if SpO₂ <90%, heart failure, or respiratory distress (avoid routine O₂ in normoxic patients)
Risk stratification: GRACE score, TIMI score - guides invasive vs conservative strategy

Step 2 - Anti-Ischemic Treatment (Relieve Pain & Ischemia)

Nitrates

Drug	Dose
Sublingual nitroglycerin	0.3-0.6 mg SL every 5 min × 3 doses
IV nitroglycerin (if pain persists)	5-10 mcg/min IV infusion, increase by 10 mcg/min every 3-5 min until relief; max 200 mcg/min. Stop if SBP <90 mmHg
Oral/topical nitrate (maintenance)	Once pain resolved; replace IV after symptom-free 12-24h

Contraindication: Avoid if hypotension or recent PDE-5 inhibitor use (sildenafil/vardenafil within 24h; tadalafil within 48h)

Beta-Blockers (give within first 24h if no contraindications)

Drug	Dose
Metoprolol succinate	25-50 mg PO once daily; titrate up
Metoprolol tartrate	5 mg IV every 5 min × 3 doses (if urgent HR/BP control), then 25-50 mg PO Q6-12h
Atenolol	25-100 mg PO once daily
Carvedilol	3.125 mg PO BD, titrate

Contraindications: Cardiogenic shock, acute decompensated heart failure, PR >0.24s, heart block, active bronchospasm

Morphine

2-4 mg IV (with or without 2-8 mg every 5-15 min as needed) - for refractory pain; use cautiously (associated with slower P2Y12 absorption)

Calcium Channel Blockers (if beta-blocker contraindicated or vasospastic angina)

Drug	Dose
Amlodipine	5-10 mg PO once daily
Diltiazem (non-DHP)	30-60 mg PO QID; SR 120-360 mg/day
Verapamil	40-120 mg PO TDS

Avoid non-DHP CCBs (diltiazem, verapamil) in heart failure with reduced EF or with beta-blockers

Step 3 - Antiplatelet Therapy (Dual Antiplatelet Therapy - DAPT)

Aspirin (give immediately, everyone)

Drug	Loading	Maintenance
Aspirin	162-325 mg PO (chewed, not swallowed whole) immediately	75-100 mg PO once daily indefinitely

P2Y12 Inhibitor - Add to Aspirin

Drug	Loading Dose	Maintenance	Notes
Ticagrelor (preferred)	180 mg PO once	90 mg PO BD for 12 months	Reversible; preferred over clopidogrel in ACS
Prasugrel (preferred if going to PCI)	60 mg PO once	10 mg PO once daily for 12 months	Avoid if age >75, weight <60 kg, or prior stroke/TIA
Clopidogrel (alternative)	300-600 mg PO once	75 mg PO once daily for 12 months	Use if ticagrelor/prasugrel not available or contraindicated

2025 ACC/AHA guideline: DAPT (aspirin + P2Y12) for minimum 12 months as default if low bleeding risk; can be shortened if high bleeding risk

GP IIb/IIIa Inhibitors (high-risk only; mainly at time of PCI)

Drug	Dose
Eptifibatide	180 mcg/kg IV bolus × 2 (10 min apart), then 2 mcg/kg/min infusion
Tirofiban	25 mcg/kg IV bolus over 3 min, then 0.15 mcg/kg/min infusion

Not recommended for routine upstream use; mainly initiated in catheterization lab for high-risk features (positive troponin, active ischemia)

Step 4 - Anticoagulant Therapy (Parenteral)

Option 1 - Enoxaparin (preferred LMWH)

Scenario	Dose
Standard	1 mg/kg SC every 12 hours
Initial IV loading (optional)	30 mg IV bolus, then 1 mg/kg SC Q12h 15 min later
CrCl <30 mL/min	1 mg/kg SC once daily
Duration	Until PCI or hospital discharge (typically 2-8 days)

Option 2 - Unfractionated Heparin (UFH)

Component	Dose
IV bolus	60 U/kg (max 4,000 U)
Infusion	12 U/kg/hr (max 1,000 U/hr)
Target aPTT	50-75 seconds (1.5-2.5× baseline)
Duration	48 hours or until PCI

Option 3 - Fondaparinux (lowest bleeding risk)

Dose	Note
2.5 mg SC once daily	Equivalent efficacy to enoxaparin but lower major bleeding risk
Avoid CrCl <20 mL/min	Requires supplemental UFH if patient goes to PCI (to prevent catheter thrombosis)

Option 4 - Bivalirudin (mainly for PCI; choice in HIT)

Dose	Note
0.75 mg/kg IV bolus, then 1.75 mg/kg/hr infusion	Used at/during PCI; stop after procedure

Do not switch between anticoagulants once started - increases bleeding risk without improving efficacy (SYNERGY trial)

Step 5 - Lipid-Lowering Therapy

High-Intensity Statin (start immediately, all patients)

Drug	Dose
Atorvastatin	40-80 mg PO once daily
Rosuvastatin	20-40 mg PO once daily

2025 ACC/AHA: If LDL ≥70 mg/dL despite maximally tolerated statin, add non-statin agent

Add-on Lipid Agents (if LDL still ≥70 mg/dL)

Ezetimibe: 10 mg PO once daily
Evolocumab (PCSK9 inhibitor): 140 mg SC every 2 weeks
Alirocumab: 75-150 mg SC every 2 weeks

Step 6 - ACE Inhibitor / ARB

Drug	Dose	Notes
Ramipril	2.5-5 mg PO BD (start low, titrate)	Start within 24h if haemodynamically stable
Lisinopril	2.5-5 mg PO once daily	Especially in reduced EF, HTN, diabetes
Enalapril	2.5-10 mg PO BD
ARB (if ACEi intolerant) - Valsartan	20-160 mg PO BD

Step 7 - Invasive Strategy (Coronary Angiography + PCI/CABG)

Risk Category	Timing
Very high risk (haemodynamic instability, cardiogenic shock, refractory ischemia, life-threatening arrhythmia, mechanical complications)	Immediate (<2h) - emergency angiography
High risk (troponin rise, dynamic ST/T changes, GRACE score >140)	Early invasive (<24h)
Intermediate risk (GRACE 109-140, recurrent symptoms, EF <40%)	Invasive within 24-72h
Low risk (no high-risk features, troponin negative)	Conservative strategy - stress test first; invasive if ischemia confirmed

Step 8 - Additional / Supportive Drugs

Drug	Dose	Indication
Aldosterone antagonist (spironolactone/eplerenone)	25-50 mg PO once daily	If EF ≤40% + heart failure or diabetes
Colchicine	0.5 mg PO BD	Post-MI pericarditis; some evidence for secondary prevention
Antiemetics (metoclopramide)	10 mg IV/IM/PO	For nausea from morphine or nitrates
Laxatives (docusate)	100-200 mg PO BD	Prevent Valsalva straining

Step 9 - Long-Term (Discharge) Medications

Drug	Purpose
Aspirin 75-100 mg OD	Lifelong antiplatelet
P2Y12 inhibitor (ticagrelor/clopidogrel)	12 months minimum
High-intensity statin	LDL target <70 mg/dL (or <55 in very high risk)
ACE inhibitor/ARB	Cardioprotection; especially if EF <40%
Beta-blocker	Minimum 1-3 years post-MI; indefinitely if EF <40%
Eplerenone/spironolactone	If EF ≤40%
Cardiac rehabilitation	All patients
Lifestyle modifications	Smoking cessation, diet, exercise

Quick Summary - Injection Doses at a Glance

Drug	Dose
Enoxaparin	30 mg IV bolus → 1 mg/kg SC Q12h (standard); 1 mg/kg SC Q24h if CrCl <30
UFH	60 U/kg IV bolus (max 4000 U) → 12 U/kg/hr infusion
Fondaparinux	2.5 mg SC once daily
Bivalirudin	0.75 mg/kg IV bolus → 1.75 mg/kg/hr infusion
Eptifibatide	180 mcg/kg IV bolus ×2 → 2 mcg/kg/min infusion
Tirofiban	25 mcg/kg IV bolus → 0.15 mcg/kg/min infusion
Morphine	2-4 mg IV PRN
IV Nitroglycerin	5-10 mcg/min, up to 200 mcg/min
Metoprolol IV	5 mg IV Q5min ×3

Sources: Harrison's Principles of Internal Medicine (22e, 2025) | Fuster & Hurst's The Heart (15e) | 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS Guideline | Tintinalli's Emergency Medicine

This is a shared conversation. Sign in to Orris to start your own chat.